Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Pharma
Novartis refreshes myelofibrosis bid as Geron flops in ph. 3
Geron's Rytelo failed to move the needle in post-JAK myelofibrosis, as Novartis is gearing up for a delayed FDA approval bid for its pelabresib.
Angus Liu
Oct 29, 2026 8:15am
Fierce Biotech
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
Oct 28, 2026 9:00am
Novartis CEO unfazed by high-profile clinical failures
Oct 27, 2026 11:40am
Rhapsido ph. 3 in MS combines superior safety with strong efficacy
Oct 26, 2026 11:05am
Novartis presses pause on Fabhalta lupus nephritis trial
Oct 19, 2026 10:13am
Novartis, Shionogi, ArriVent—Fierce Pharma Asia
Oct 9, 2026 8:30am
